The behavioral and convulsant effects of cefazolin, a I-lactam derivative, were studied after intraperitoneal administration to DBA/2 mice, a strain genetically susceptible to sound-induced seizures, and Swiss mice.
pefloxacin > enoxacin > ofloxacin > rufloxacin > norfloxacin > cinoxacin > ciprofloxacin > nalidixic acid. The relationships between the chemical structures and proconvulsant activities of quinolone derivatives were studied. The relationship between lipophilicity and proconvulsant activity was also investigated.
The genetically epilepsy-prone mouse or Dilute Brown Agouti DBA/2J (DBA/2) mouse has been known since 1947 to be a strain susceptible to audiogenic seizures (AGSs) (21) . The characteristics and neurochemical abnormalities of this mouse strain have been described by various researchers (6, 35, 36, 40) . Between 16 and 30 days of age in response to a loud tone, this mouse strain shows ill-coordinated locomotion consisting of a wild running followed by rhythmic clonic jerking with the animal lying on one side, followed by tonic flexion and tonic extension of trunk, limbs, and tail. The latter phase may terminate with respiratory arrest and death. One investigator observed a longer period of susceptibility to AGSs of up to 39 days (45) , and he has interpreted this phenomenon as the consequence of differences in genetic composition among the strains. In addition, it has been reported that DBA/2 mice have increased seizure susceptibility to a variety of nonaudiogenic convulsant treatments, including chemical and physical stimuli (6, 7, 19) . At 8 weeks of age, when DBA/2 mice are not susceptible to AGSs, they still showed major hyperexcitability in response to electrically induced convulsions, even after development of resistance to AGSs (6, 19) . Extensive studies were done on the nature of AGSs in DBA/2 mice; a defect in uptake or utilization of glucose at the critical age was observed and proposed to be the primary cause of seizure susceptibility (37) . Ca2"-ATPase pathology was observed and appeared to be another factor which influences AGS susceptibility (31, 32) . Measurements of neurotransmitter concentrations and activities of enzymes involved in neurotransmitter synthesis or further metabolism, as well as studies of receptor binding sites, had showed no differences in the levels of the inhibitory and excitatory amino acids in the cerebellum or regions concerned with the auditory pathway (auditory cortex, cochlear nuclei, and inferior colliculi) (6, 9, 43) . As far as y-aminobutyric acid (GABA) is concerned, it was demonstrated that GABA inhibitory input is decreased in the central nervous systems of DBA/2 mice at 3 weeks, but not at 8 weeks, and that this effect is greater on the receptor than on the ionophore. In addition, GABA-and benzodiazepinebinding sites exhibited regional and age-dependent variation * Corresponding author.
in DBA/2 mice and a reduction of [3HJGABA-binding sites in whole brain was described by several investigators (22, 23, 42) . A decrease in the number of benzodiazepine-binding sites was reported for whole brains of DBA/2 mice at the seizure-susceptible age by Horton and coworkers (22) . The major susceptibility to excitatory amino acid agonists, such as kainate, N-methyl-D-aspartate, and homocysteine thiolactone, in this strain of mice in comparison with C57 mice suggests increased endogenous (central nervous system) excitatory responsiveness in DBA/2 mice (19) . Thus, this strain of mice has been considered an excellent animal model for the study of certain kinds of human epilepsy and for testing of new anticonvulsant drugs (6, 39) .
Since cefazolin has been known to induce convulsions in various animal species (12, 13, 29, 30) , it was postulated that the patterns of responsiveness to this convulsant agent may be different in AGS-susceptible DBA/2 mice and non-AGSsusceptible Swiss mice. The convulsant action of penicillins and cephalosporins has been attributed to inhibition of the GABA system (2, 10, 21) . The main intention of this study was to examine cefazolin-induced seizures in AGS-prone DBA/2 mice and in Swiss mice. In addition, some experimental experiences with quinolones (1, 11) have demonstrated possible proconvulsant activity. Thus, the neurotoxic effects of quinolones and the inhibitory effects of cefazolin on GABA transmission prompted us to study the effects of their concomitant administration. In the present report, the proconvulsant effects of several quinolones are also described, compared, and discussed with particular regard to the structure-activity relationship and lipophilicity. MATERIALS (41) . Relative convulsant activities were also determined by comparison of respective CD50s.
Lipophilicity measurements. The relative lipophilicity (Rm) of the compounds was measured by reversed-phase thinlayer chromatography as previously described (5 
RESULTS
Comparative convulsant activities of cefazolin in Swiss and AGS-prone mice. As shown in Table 1 , the intensities of seizures were significantly different in the two strains of mice studied after i.p. administration of cefazolin. In particular, DBA/2 mice were more susceptible to convulsant doses of cefazolin than were Swiss mice. Higher doses of cefazolin were necessary in Swiss mice for a similar incidence of the clonic and tonic seizure phases (Table 1) .
Combined treatment of DBA/2 mice with cefazolin and quinolones. A second group of animals (DBA only) was treated with some quinolones at a dose of 250 nmol/g (which corresponds to approximately 100 p,g/g) or the vehicle (sterile saline), and 60 min later the same animals were injected i.p. with various doses of cefazolin. At 250 nmollg, each quinolone was unable to elicit seizures in DBA/2 mice and elicited a mild decrease in spontaneous activity and explorative behavior. The effects of combined treatment of cefazolin with nalidixic acid, cinoxacin, ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin, or rufloxacin are shown in Table 2 . Significant differences in the proconvulsant effects of the quinolones tested were observed. The relative CD50s
(with 95% confidence limits) of cefazolin alone and different quinolones plus cefazolin are reported in Table 3 .
The concentration of cefazolin which produced a high incidence of seizures was lower after administration of equimolar doses of pefloxacin than with the other quinolones tested. The percentage of DBAI2 mice showing seizures when pretreated with 250 nmol of pefloxacin per g 1 h before they received cefazolin was, in some cases, significantly increased (P < 0.05) in comparison with the group of mice that received cefazolin alone. Similar and less evident effects were observed in DBA/2 mice pretreated with an equimolar dose (250 nmol/g) of enoxacin, norfloxacin, ofloxacin, ru- floxacin, or cinoxacin. Ciprofloxacin and nalidixic acid were still less able to increase the convulsant properties of cefazolin. In particular, ciprofloxacin and nalidixic acid failed to modify the occurrence of cefazolin-induced seizures significantly compared with the cefazolin group by both Fisher's exact probability test and the Mann-Whitney U test.
ECoG activity. In animals used to study ECoG activity, electrocorticographic epileptic discharges appeared more rapidly in mice pretreated with quinolones than in those that received cefazolin alone. In particular, these epileptic discharges appeared more rapidly in animals pretreated with pefloxacin than in those pretreated with ciprofloxacin or nalidixic acid. The animals pretreated with the other quinolones showed an occurrence of electrocorticographic epileptic discharges with a latency intermediate between those of pefloxacin and ciprofloxacin (data not shown). The electrocorticographic epileptic pattern was similar in DBA/2 mice that received cefazolin alone or a quinolone derivative plus cefazolin ( Fig. 2 and 3) .
Physicochemical parameters. The Rm and pK. values and molecular weights of the quinolone derivatives tested are summarized in Table 4 .
DISCUSSION
The present study demonstrated marked differences between Swiss and DBA/2 mice in response to seizures induced by cefazolin. In particular, seizure latency was consistently shorter in DBA/2 mice than in Swiss mice. In fact, a difference in seizure incidence was observed and Swiss mice showed an increase in clonic seizure latency or the latter phase of seizures failed to occur. These data suggest that the neural mechanisms which delay or prevent the onset of clonic seizures are not present in DBA/2 mice; this is in agreement with previous studies which showed that DBA/2 mice have increased seizure susceptibility to a variety of nonaudio convulsant treatments (6, 7, 19) .
Since previous studies have indicated that systemic administration of cefazolin to experimental animals produces epileptogenic effects (12, 13, 24, 29, 30) and that quinolones may be responsible for neurotoxic effects in humans and experimental animals (1, 3, 4, 11), the present results further confirm these effects. In fact, the combination of quinolones and cefazolin induced more marked convulsant effects than cefazolin alone in experimental animals. The convulsant action of 1-lactam derivatives has been related to reduction of GABA release from nerve terminals or inhibition of the binding of GABA to its receptor sites (2, 10, 21) . In a previous study, we suggested that cefazolin is a tetrazol derivative which shows marked similarity to pentylenetetrazol, a well-known convulsant drug (12) .
Although the mechanism by which quinolones exhibit a proconvulsant effect is still obscure, the compounds tested showed different degrees of potency. Thus, we attempted to clarify the relationship between the structures and the epileptogenic activities of quinolones. Chemically, the new quinolones tested in this study are generally characterized by having a fluorine atom at the C-6 position and a piperazine moiety at position 7 of the quinoline or naphthyridine ring. Pefloxacin and enoxacin seem to be the most potent convulsant compounds of our series (Tables 2 and 3 ). However, pefloxacin has a quinoline structure while enoxacin has a naphthyridine structure. Both pefloxacin and enoxacin possess a piperazine moiety at position 7, like ofloxacin, ciprofloxacin, rufloxacin, and norfloxacin. We also examined cinoxacin, which seems to be less potent than pefloxacin and enoxacin but more potent than ciprofloxacin. Cinoxacin has no fluorine atom at position 6 and has a nitrogen atom in position 2 of the quinoline ring. Nalidixic acid, a 1,8-naphthyridine derivative which does not possess a fluorine atom in its ring, showed a minimum convulsant effect. These results suggest that either the presence of the fluorine atom or the presence of the quinoline and the naphthyridine ring seems to be significantly responsible for the proconvulsant effects of quinolones. Since differences among the different compounds studied exist, we suspect that both the presence of the fluorine atom and the presence of the quinoline and naphthyridine structures might affect the capacity of quinolones to penetrate the brain. Differences among the abilities of quinolones to enter the brain through the blood-brain barrier exist, and recent data suggest that the concentrations of ciprofloxacin in cerebral fluid are approximately 2 to 5% (up to 10%) of the concomitant concentrations in serum in patients with noninflamed meninges and 2.5 times higher levels have been detected in the presence of inflammation (8) . Levels of ofloxacin and pefloxacin in cerebrospinal fluid were higher than those of ciprofloxacin (28) . In addition, concentrations of ofloxacin in cerebrospinal fluid were 50 to 60% of those in serum in patients with bacterial meningitis, and pefloxacin also penetrated the brain well in patients with inflamed meninges (8) . These differences among the abilities of various quinolones to penetrate the blood-brain barrier may, in part, explain the major neurotoxicity of some compounds. Thus, the various degrees of proconvulsant activity exhibited by these derivatives, which do not ionize appreciably at physiological pH, may be partially related to their lipophilicity ( 1.25 100 90 70 50 3.1 1.5 100 100 90 60 3.5 a Groups of 10 DBA/2 mice were injected i.p. with some quinolones and 1 h later with the stated doses of cefazolin and observed for 240 min after cefazolin injection. The incidence of each seizure phase is expressed as the percentage of mice in each group displaying that phase. Significant differences in the incidence of seizure phases between concurrent control (cefazolin alone; see Table 1 ) and drug-treated (quinolones plus cefazolin) groups are marked with the symbols * (P < 0.05) and ** (P < 0.01). WR, wild running; RA, respiratory arrest; SR, arithmetic mean of the maximum individual responses for each animal in the group. The median seizure score ± the standard error of the mean is reported for each dose level studied. Significant differences in the incidence of seizure phases between concurrent cefazolin alone (see Table 1 ) and quinolones plus cefazolin groups are marked with the symbols + (P < 0.05) and ++ (P < 0.01) (Mann-Whitney U test).
lation of in vivo concentrations of drugs demonstrated that pefloxacin was the most lipophilic quinolone (8) . Moreover, we can suppose that at the concentrations reached by the drug in the brain it may leave the cerebral area very slowly.
A possible interaction of these compounds with GABA receptor-binding sites has been reported (17, 38, 44) .
However, the fact that compounds with different potencies as inhibitors of specific GABA binding, such as ciprofloxacin, rufloxacin, norfloxacin, and enoxacin, and very similar Rm values showed different degrees of proconvulsant activity suggests the importance of other parameters. Tsuji and coworkers (44) have previously considered the relationship between GABA receptor affinity (Ki values) and lipophilicity (apparent partition coefficient) for various quinolones. They suggested that the increasing lipophilic character may be responsible for possible electrostatic interactions between GABA receptors and quinolones. This may be responsible for nonspecific adsorption on the lipoidal membranes, which increases with the increasing lipophilic char- acter of the drug. However, the concentration needed for interaction of a quinolone and GABA is rather high and varied among the different quinolones tested by a factor of -100. Thus, it appears questionable that a specific interaction of quinolones with the GABA receptor can explain the proconvulsant activity of these compounds (16) . The proconvulsant activity of quinolone derivatives on pentylenetetrazol-induced seizures in mice was recently studied (18) , and the results obtained were, in part, similar to those obtained with DBA/2 mice concomitantly administered quinolones and cefazolin.
Since some quinolones have been shown to be responsible for important pharmacokinetic interactions, for example, with xanthines, this possible mechanism also deserves consideration in this case (26, 33, 46) . The differences in protein binding and penetration into the brain may also explain the toxicity differences observed in the present study, which are similar to those reported by two recent studies of Dimpfel and coworkers (15, 16) . Indeed, in both studies ciprofloxacin was the quinolone with the least ability to induce neurotoxic changes.
Nalidixic acid is well known as a drug which possesses a lot of central nervous system side effects, and the recent studies of Dimpfel and coworkers (15, 16) have demonstrated that this compound is highly active in hippocampal slices, while it appeared to be completely unable to enhance seizures induced by cefazolin in our study. This phenomenon seems to be due to the high level of protein binding of nalidixic acid and to its poor penetration of the brain (data not shown). These differences between the study of Dimpfel and coworkers (15, 16) and ours may be due to the fact that the first two studies evaluated the effects of quinolones in vitro by direct application of these compounds to hippocampal slices, while we used a whole-animal model in which we may observe some pharmacokinetic effects of drugs in a more biologically relevant situation which usually appears in clinical experience. We suppose that quinolones may act by enhancing the central nervous system side effects induced by cefazolin. In addition, the presence of a common route of excretion for quinolones and cefazolin (glomerular filtration and tubular secretion) might be considered (28) . Quinolones and cefazolin are both organic acids and therefore may compete for elimination if they are given concomitantly. Moreover, this interaction would be potentially responsible for increased concentrations in serum and prolonged effects of one or both drugs.
Further experiments are necessary to clarify whether concomitant administration of quinolones and cefazolin results in altered elimination of either compound or both.
